Individualizing hormone-therapy according to cardiovascular risk

Area of Science:

• Reproductive Endocrinology
• Cardiovascular Health
• Menopause Management

Background:

• Growing consensus supports hormone therapy (HT) for healthy, low-risk women.
• Specific age and time-since-menopause windows are critical for optimal benefit-risk.
• Cardiovascular disease (CVD) risk factors necessitate individualized HT approaches.

Purpose of the Study:

• To evaluate the benefit-to-risk profile of hormone therapy.
• To identify specific patient populations requiring special considerations for hormone therapy initiation.
• To inform clinical decision-making regarding hormone therapy in diverse menopausal populations.

Main Methods:

• Review of current clinical consensus and guidelines.
• Analysis of epidemiological data on hormone therapy outcomes.
• Risk-benefit assessment based on age and time since menopause.

Main Results:

• High benefit-to-risk ratio for hormone therapy in healthy women <60 years old within 10 years of menopause.
• Increased risks or altered benefits for women outside these parameters.
• Cardiovascular risk factors significantly modify the hormone therapy benefit-risk assessment.

Conclusions:

• Hormone therapy is highly beneficial for a defined group of healthy menopausal women.
• Individualized assessment is crucial for women with cardiovascular risks or outside standard initiation criteria.
• Further research may be needed to refine HT recommendations for specific subgroups.